PE20080982A1 - Metodos para dosificar un 1,2,4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido - Google Patents
Metodos para dosificar un 1,2,4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentidoInfo
- Publication number
- PE20080982A1 PE20080982A1 PE2007001386A PE2007001386A PE20080982A1 PE 20080982 A1 PE20080982 A1 PE 20080982A1 PE 2007001386 A PE2007001386 A PE 2007001386A PE 2007001386 A PE2007001386 A PE 2007001386A PE 20080982 A1 PE20080982 A1 PE 20080982A1
- Authority
- PE
- Peru
- Prior art keywords
- senseness
- oxadiazole
- dosing
- methods
- orally active
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title abstract 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- -1 2-FLUORO-PHENYL Chemical class 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- 206010011732 Cyst Diseases 0.000 abstract 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001647 drug administration Methods 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
SE REFIERE A REGIMENES DE ADMINISTRACION VIA ORAL DEL ACIDO 3-[5-(2-FLUORO-FENIL)-[1,2,4]OXADIAZOL-3-IL]-BENZOICO; DONDE LA PRIMERA DOSIS ES DE 20mg/kg, LA SEGUNDA ES DE 20mg/kg Y LA TERCERA ES DE 40mg/kg, ADMINISTRADOS CADA 6 hrs POR 14 DIAS. DICHO REGIMEN DE ADMINISTRACION MEDICAMENTOSA TIENE UN AUC0-24866 µg, Cmax DE 76 µg/mL y Cmin 9,6 µg/mL EL PRIMER DIA DE ADMINISTRACION Y ES UTIL EN EL TRATAMIENTO O PREVENCION DE ENFERMEDADES ASOCIADAS A MUTACIONES SIN SENTIDO MANIFESTADAS POR LA TRASLACION O DEGENERACION PREMATURA DE ARNm, COMO FIBROSIS QUISTICA, DISTROFIA MUSCULAR DUCHENNE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85145006P | 2006-10-12 | 2006-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080982A1 true PE20080982A1 (es) | 2008-07-19 |
Family
ID=39102963
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001386A PE20080982A1 (es) | 2006-10-12 | 2007-10-12 | Metodos para dosificar un 1,2,4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido |
| PE2020002230A PE20212245A1 (es) | 2006-10-12 | 2007-10-12 | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico |
| PE2011001559A PE20120670A1 (es) | 2006-10-12 | 2007-10-12 | Metodos para dosificar un 1, 2, 4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido |
| PE2016000659A PE20160947A1 (es) | 2006-10-12 | 2007-10-12 | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002230A PE20212245A1 (es) | 2006-10-12 | 2007-10-12 | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico |
| PE2011001559A PE20120670A1 (es) | 2006-10-12 | 2007-10-12 | Metodos para dosificar un 1, 2, 4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido |
| PE2016000659A PE20160947A1 (es) | 2006-10-12 | 2007-10-12 | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9226919B2 (es) |
| EP (2) | EP2073805B1 (es) |
| JP (4) | JP2010506840A (es) |
| KR (4) | KR20160128468A (es) |
| CN (2) | CN101553226B (es) |
| AU (1) | AU2007308067B2 (es) |
| BR (2) | BRPI0719276A2 (es) |
| CA (1) | CA2675518C (es) |
| CL (1) | CL2007002923A1 (es) |
| DK (1) | DK2073805T3 (es) |
| ES (1) | ES2538359T3 (es) |
| HR (1) | HRP20150590T1 (es) |
| IL (2) | IL198147A (es) |
| MX (1) | MX2009003909A (es) |
| NO (1) | NO342061B1 (es) |
| PE (4) | PE20080982A1 (es) |
| PL (1) | PL2073805T3 (es) |
| PT (1) | PT2073805E (es) |
| RS (1) | RS54025B1 (es) |
| RU (1) | RU2462247C2 (es) |
| SI (1) | SI2073805T1 (es) |
| TW (1) | TWI405570B (es) |
| WO (1) | WO2008045566A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2887054T3 (es) | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| IN2014CN04406A (es) | 2006-03-30 | 2015-09-04 | Ptc Therapeutics Inc | |
| RU2462247C2 (ru) | 2006-10-12 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2015134711A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| LT3524595T (lt) | 2014-08-28 | 2022-09-26 | Eisai R&D Management Co., Ltd. | Aukšto grynumo chinolino darinys ir jo gamybos būdas |
| US20180028662A1 (en) * | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| CN108348527A (zh) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| TWI801438B (zh) | 2017-10-19 | 2023-05-11 | 中國大陸商軒竹（北京）醫藥科技有限公司 | 抗菌胺基糖苷類似物之合成 |
| US11203578B2 (en) | 2017-11-23 | 2021-12-21 | Universita'degli Studi Dipalermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| KR20210151131A (ko) * | 2019-04-10 | 2021-12-13 | 피티씨 테라퓨틱스, 인크. | 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법 |
| WO2022177267A1 (ko) * | 2021-02-16 | 2022-08-25 | 라이보텍(주) | 넌센스-매개 mrna 분해를 억제하기 위한 화합물 |
| KR102378381B1 (ko) * | 2021-08-23 | 2022-03-24 | 라이보텍(주) | 넌센스-매개 mRNA 분해를 억제하기 위한 화합물 |
| WO2022241030A1 (en) * | 2021-05-11 | 2022-11-17 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
| KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
| CN119638642A (zh) * | 2023-12-12 | 2025-03-18 | 暨南大学 | 双环类化合物及其药物组合物和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2002313633B2 (en) | 2001-06-08 | 2007-03-01 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| JP2006506340A (ja) | 2002-08-09 | 2006-02-23 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| ES2887054T3 (es) * | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| WO2004110351A2 (en) | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
| CN1905856A (zh) * | 2003-12-23 | 2007-01-31 | 阿尔扎公司 | 用于增加受控递送的药物组合物的溶解度的方法和剂型 |
| DK1874306T3 (da) * | 2005-04-08 | 2012-10-01 | Ptc Therapeutics Inc | Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi |
| US20070010553A1 (en) | 2005-07-01 | 2007-01-11 | Astrazeneca Ab | New use |
| BRPI0716996B8 (pt) | 2006-09-08 | 2021-05-25 | Ptc Therapeutics Inc | processo para preparar um composto |
| US7863456B2 (en) | 2006-09-25 | 2011-01-04 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid |
| RU2462247C2 (ru) * | 2006-10-12 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию |
-
2007
- 2007-10-11 RU RU2009117590/15A patent/RU2462247C2/ru active
- 2007-10-11 DK DK07852738.9T patent/DK2073805T3/da active
- 2007-10-11 EP EP07852738.9A patent/EP2073805B1/en active Active
- 2007-10-11 BR BRPI0719276-2A2A patent/BRPI0719276A2/pt not_active Application Discontinuation
- 2007-10-11 CA CA2675518A patent/CA2675518C/en active Active
- 2007-10-11 AU AU2007308067A patent/AU2007308067B2/en not_active Ceased
- 2007-10-11 HR HRP20150590TT patent/HRP20150590T1/hr unknown
- 2007-10-11 PL PL07852738T patent/PL2073805T3/pl unknown
- 2007-10-11 JP JP2009532453A patent/JP2010506840A/ja active Pending
- 2007-10-11 CL CL200702923A patent/CL2007002923A1/es unknown
- 2007-10-11 EP EP12152282.5A patent/EP2460520B1/en active Active
- 2007-10-11 KR KR1020167030361A patent/KR20160128468A/ko not_active Ceased
- 2007-10-11 BR BR122019020961A patent/BR122019020961B8/pt active IP Right Grant
- 2007-10-11 RS RS20150384A patent/RS54025B1/sr unknown
- 2007-10-11 WO PCT/US2007/021921 patent/WO2008045566A1/en not_active Ceased
- 2007-10-11 ES ES07852738.9T patent/ES2538359T3/es active Active
- 2007-10-11 CN CN200780045655.9A patent/CN101553226B/zh not_active Expired - Fee Related
- 2007-10-11 PT PT78527389T patent/PT2073805E/pt unknown
- 2007-10-11 SI SI200731657T patent/SI2073805T1/sl unknown
- 2007-10-11 CN CN201310098430.7A patent/CN103211766B/zh not_active Expired - Fee Related
- 2007-10-11 MX MX2009003909A patent/MX2009003909A/es active IP Right Grant
- 2007-10-11 KR KR1020177023924A patent/KR20170100072A/ko not_active Ceased
- 2007-10-11 KR KR1020097009602A patent/KR20090074231A/ko not_active Ceased
- 2007-10-11 KR KR1020157013882A patent/KR101758341B1/ko not_active Expired - Fee Related
- 2007-10-11 US US11/974,068 patent/US9226919B2/en active Active
- 2007-10-12 TW TW096138340A patent/TWI405570B/zh not_active IP Right Cessation
- 2007-10-12 PE PE2007001386A patent/PE20080982A1/es not_active Application Discontinuation
- 2007-10-12 PE PE2020002230A patent/PE20212245A1/es unknown
- 2007-10-12 PE PE2011001559A patent/PE20120670A1/es not_active Application Discontinuation
- 2007-10-12 PE PE2016000659A patent/PE20160947A1/es unknown
-
2009
- 2009-04-16 IL IL198147A patent/IL198147A/en active IP Right Grant
- 2009-05-08 NO NO20091826A patent/NO342061B1/no unknown
-
2013
- 2013-10-25 JP JP2013222531A patent/JP6129713B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-30 IL IL236519A patent/IL236519A/en active IP Right Grant
-
2015
- 2015-10-08 JP JP2015200029A patent/JP6333227B2/ja not_active Expired - Fee Related
- 2015-12-17 US US14/972,269 patent/US9522137B2/en not_active Expired - Fee Related
-
2016
- 2016-11-08 US US15/345,748 patent/US9737513B2/en not_active Expired - Fee Related
- 2016-12-08 JP JP2016238230A patent/JP2017081946A/ja active Pending
-
2017
- 2017-07-07 US US15/643,724 patent/US9877952B2/en active Active
-
2018
- 2018-01-19 US US15/875,296 patent/US10172836B2/en active Active
- 2018-12-04 US US16/208,663 patent/US10849885B2/en not_active Expired - Fee Related
-
2020
- 2020-10-23 US US17/078,092 patent/US20210038572A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080982A1 (es) | Metodos para dosificar un 1,2,4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido | |
| Kast et al. | A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care | |
| Ranganath et al. | Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy | |
| JP2015083580A5 (es) | ||
| JP2009138003A5 (es) | ||
| MA34296B1 (fr) | Composition retard injectable antipsychotique | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| JP2011105733A5 (es) | ||
| JP2009269923A5 (es) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2020536854A5 (es) | ||
| Attia et al. | Pharmaceutical polymers and P-glycoprotein: Current trends and possible outcomes in drug delivery | |
| Chithra et al. | Advanced nanomicelles for targeted glioblastoma multiforme therapy | |
| Hopster et al. | Pharmacology of the equine foot: medical pain management for laminitis | |
| Castillo‐Torres et al. | Intermittent apomorphine use for off period rescue in Parkinson's disease: a pragmatic review of over three decades of clinical experience | |
| JP2011500589A5 (es) | ||
| JP2012505830A5 (es) | ||
| JP2005533830A5 (es) | ||
| Lawson et al. | Current developments in intraspinal agents for cancer and noncancer pain | |
| TWI302912B (en) | Therapeutic use | |
| JP2020510043A5 (es) | ||
| JP2016538295A5 (es) | ||
| Yadav et al. | Next generation tuberculosis therapy: from drug design to delivery | |
| Crumbaker et al. | Dose considerations for anti‐cancer drugs in metastatic prostate cancer | |
| Hagedorn et al. | Intrathecal analgesics: Choices and optimization of delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |